Silk Road Medical, Inc (NASDAQ:SILK) Released Earnings Last Week And Analysts Lifted Their Price Target To US$18.43
A week ago, Silk Road Medical, Inc (NASDAQ:SILK) came out with a strong set of full-year numbers that could potentially lead to a re-rate of the stock. Silk Road Medical beat expectations with revenues of US$177m arriving 3.1% ahead of forecasts. The company also reported a statutory loss of US$1.44, 3.7% smaller than was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Check out our latest analysis for Silk Road Medical
Taking into account the latest results, the most recent consensus for Silk Road Medical from nine analysts is for revenues of US$195.7m in 2024. If met, it would imply a decent 10% increase on its revenue over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$1.38. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$191.4m and losses of US$1.46 per share in 2024. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for both revenues and losses per share.
It will come as no surprise to learn thatthe analysts have increased their price target for Silk Road Medical 26% to US$18.43on the back of these upgrades. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Silk Road Medical at US$28.00 per share, while the most bearish prices it at US$8.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Silk Road Medical's revenue growth is expected to slow, with the forecast 10% annualised growth rate until the end of 2024 being well below the historical 28% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.8% annually. So it's pretty clear that, while Silk Road Medical's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.
The Bottom Line
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Silk Road Medical analysts - going out to 2026, and you can see them free on our platform here.
You still need to take note of risks, for example - Silk Road Medical has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
